Lakhmir S. Chawla & John A. Kellum in “nature” * We believe that some existing biomarkers such as NGAL will begin to shape clinical practice…..

Roy Zwanziger Alere (Inverness) Q&A about 1,6 billion dollars paid for Biosite ;“…I would say that if NGAL comes in reasonable, Biosite was a very cheap acquisition…”

Dr. Khurana, Singapore **    “NGAL has several characteristics of an ideal biomarker”

D., Bellomo Austin Hospital ” Our findings suggest an important analogy between the troponin/creatine kinase relationship in acute myocardial infarction and the NGAL/creatinine relationship in AKI 


Conflicting interests?




About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.